TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31809622
Drug: Androgen receptor
Normalized name: Androgen receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen receptor splice variant 7 (AR‐V7) mRNA expression in hormone-sensitive prostate cancer (HSPC) and castration-resistant prostate cancer (CRPC)
Study: 29405668
Drug: Meloxicam (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam (10 mg in 10 mL saline)
Study: 24337625
Drug: CIK treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIK treatment plus standard treatment
Study: 20823097
Drug: Rolofylline 30
Normalized name: Rolofylline
DrugBank: Rolofylline (DB12670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rolofylline 30 mg administered as a 4 h infusion
Study: 11443569
Drug: Nitazoxanide 500‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitazoxanide 500‐mg tablet twice daily for 3 days
Study: 31728675
Drug: Single standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single standard dose of sucrose 2 min before heel prick
Study: 31728675
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose of sucrose 2 min before and 30 s after heel prick
Study: 27312122
Drug: Oral product
Normalized name: Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral product alone (ZO-1)
Study: 27312122
Drug: Oral product
Normalized name: Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral product with topical product (ZO-2 + ZT)
Study: 27312122
Drug: Combination active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination active groups (ZO-2 + ZT)
Study: 27312122
Drug: Dietary supplement
Normalized name: dietary supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplement alone (ZO-1)
Study: 18754720
Drug: Prophylactic low-level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic low-level laser therapy (LLLT)
Study: 18754720
Drug: Therapeutic low-level
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic low-level laser therapy (LLLT)
Study: 17056950
Drug: Paracetamol 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 1000 mg IV
Study: 14616463
Drug: Cranberry juice
Normalized name: cranberry juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry juice (500 mL diluted with 1500 mL tap water for 2 weeks)
Study: 14616463
Drug: Tap water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tap water (2000 mL for 2 weeks)
Study: 16344024
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of oxymorphone immediate release (IR)
Study: 2117625
Drug: Ribavirin 1200
Normalized name: ribavirin 1200 Dose Pack, 4 Unit Dose Packs, 14 Tablets Each
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribavirin 1200 mg
Study: 2117625
Drug: Ribavirin 1600
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin 1600 mg
Study: 6452805
Drug: Zimelidine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zimelidine (100 mg at night, increasing to 200 mg after two weeks)
Study: 6452805
Drug: Amitriptyline (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (75 mg at night, increasing to 150 mg after two weeks)
Study: 31604060
Drug: Low-Level Laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Level Laser Therapy (LLLT) applied at 5 intraoral points for 30 seconds each on one side (laser group)
Study: 26507618
Drug: Fixed-Dose Combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-Dose Combination (FDC) of aspirin and clopidogrel
Study: 26507618
Drug: Separate Dual
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate Dual Pills (SDP) of aspirin and clopidogrel
Study: 21559284
Drug: Intravenous GH
Normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous GH bolus plus an oral glucose load (OGTT)
Study: 21559284
Drug: Intravenous saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous saline plus OGTT
Study: 19264678
Drug: Imatinib <350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib <350 mg daily
Study: 11240262
Drug: Five-field segmented
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five-field segmented irradiation technique with a planned dose of 78 Gy.
Study: 31081504
Drug: Nintendo WiiFit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintendo WiiFit balance training, conducted twice a week for 3 months.
Study: 23564361
Drug: Manual circumlaryngeal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual circumlaryngeal therapy for 20 minutes
Study: 8551476
Drug: Amnioinfusion (300-500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amnioinfusion (300-500 mL bolus and 125-150 mL/h constant drip)
Study: 1699835
Drug: IV albumin
Normalized name: albumin human, USP Injection [Albuminar]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV albumin (8 g/L of ascitic fluid removed)
Study: 1699835
Drug: IV dextran-70
Normalized name: Dextran 70
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV dextran-70 (8 g/L of ascitic fluid removed)
Study: 507789
Drug: Amoxicillin and
Normalized name: omeprazole, amoxicillin and rifabutin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin and probenecid
Study: 29489484
Drug: 800-kcal, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800-kcal, 20 g fat, and 70 g protein diet for 1 week before liver resection
Study: 26121998
Drug: Telephone-delivered multiple
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-delivered multiple health behaviour change intervention using acceptance commitment therapy strategies
Study: 26121998
Drug: Health professional
Normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health professional visits and medications
Study: 21482566
Drug: Ceftaroline fosamil
Normalized name: Ceftaroline fosamil
DrugBank: Ceftaroline fosamil (DB06590)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftaroline fosamil 600 mg iv every 12 h
Study: 21482566
Drug: Ceftriaxone 1
Normalized name: ceftriaxone 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 1 g iv every 24 h
Study: 16398939
Drug: Carboplatin (AUC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin (AUC 5) plus paclitaxel (175 mg/m2) every 3 weeks for 6 cycles
Study: 3427552
Drug: Prenylamine (PNL)
Normalized name: prenylamine
DrugBank: Prenylamine (DB04825)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenylamine (PNL) 200 mg/day
Study: 3427552
Drug: Adriamycin (ADM)
Normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adriamycin (ADM) at standard oncological doses up to 550 mg/m2 plus placebo
Study: 11467701
Drug: Mifepristone 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 50 mg followed by gemeprost 0.5 mg
Study: 11467701
Drug: Mifepristone 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 50 mg followed by gemeprost 1.0 mg
Study: 11467701
Drug: Mifepristone 200
Normalized name: mifepristone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 200 mg followed by gemeprost 0.5 mg
Study: 11467701
Drug: Mifepristone 200
Normalized name: mifepristone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 200 mg followed by gemeprost 1.0 mg
Study: 2638181
Drug: Triclosan/zinc formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triclosan/zinc formulations
Study: 28118272
Drug: Nonsteroidal anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroidal anti-inflammatory drugs for 10 days (same for both groups)
Study: 23608246
Drug: Cabergoline starting
Normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cabergoline starting on the day of HCG injection
Study: 21279990
Drug: R788 (fostamatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: R788 (fostamatinib disodium) 100 mg twice daily
Study: 18640170
Drug: HPV 16
Normalized name: HPV 16 E7/HSP65 vaccine
DrugBank: Verpasep caltespen (DB04959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV 16 and 18 vaccine (3 doses)
Study: 14641395
Drug: Nurse telephone
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse telephone calls intervention applied for 12 weeks, consisting of education and reinforcement of diet, exercise, medication adjustment recommendations, and self-monitoring of blood glucose levels.
Study: 9241127
Drug: Intermittent etidronate
Normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent etidronate (400 mg per day for 14 days) followed by calcium (500 mg per day for 76 days), given for four cycles
Study: 3524231
Drug: mazindol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: mazindol (2 mg daily)
Study: 1889143
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg pirenzepine
Study: 1889143
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg pirenzepine at night
Study: 3902672
Drug: Timolol 20
Normalized name: timolol 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol 20 mg once daily
Study: 27784751
Drug: Adjunctive brexpiprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive brexpiprazole
Study: 20189174
Drug: Zhibitai (480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zhibitai (480 mg orally twice daily)
Study: 20189174
Drug: Atorvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (10 mg orally once a day)
Study: 20189174
Drug: Both Zhibitai
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both Zhibitai and Atorvastatin
Study: 15497510
Drug: Regular insulin
Normalized name: Regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular insulin (n=10)
Study: 8313183
Drug: Dihydroartemisinin (360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroartemisinin (360 mg in 5 days and 480 mg in 7 days)
Study: 31122494
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy with cilostazol (100 mg, twice per day) and aspirin or clopidogrel
Study: 31122494
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with aspirin (81 or 100 mg, once per day) or clopidogrel (50 or 75 mg, once per day)
Study: 25134047
Drug: Prescription group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription group (n = 32) given a take-home supply of oral naltrexone
Study: 21716267
Drug: S-ketamine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-ketamine (0.2 mg/kg) after pretreatment with ticlopidine (250 mg twice daily)
Study: 21716267
Drug: S-ketamine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-ketamine (0.2 mg/kg) after pretreatment with itraconazole (200 mg once daily)
Study: 16833023
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg risperidone tablet
Study: 8096475
Drug: 5% glucose
Normalized name: Dextrose/Water 5% Oral Solution [ENFAMIL 5% GLUCOSE IN WATER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% glucose infusion
Study: 11048829
Drug: No glucose
Normalized name: No glucose hemofiltration solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: No glucose infusion (control)
Study: 22209361
Drug: Lu AA21004
Normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lu AA21004 10 mg
Study: 22901346
Drug: Lu AA21004
Normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lu AA21004 1 mg
Study: 22209361
Drug: Lu AA21004
Normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lu AA21004 5 mg
Study: 20445497
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral sodium bicarbonate
Study: 9715485
Drug: Topical prednisolone
Normalized name: prednisolone Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical prednisolone acetate
Study: 27063162
Drug: Intensive statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive statin therapy (atorvastatin, 80 mg/day, 3 days before till 3 days after intervention)
Study: 27063162
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (atorvastatin, 20 mg/day)
Study: 23185751
Drug: CMM +
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CMM + chemotherapy (189 cases)
Study: 23185751
Drug: Chemotherapy (177
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (177 cases)
Study: 20400920
Drug: Target-controlled infusion
Normalized name: Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
DrugBank: Tagraxofusp (DB14731)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Target-controlled infusion (TCI) of remifentanil (0.8 ng · mL as effect-site target)
Study: 20400920
Drug: Manually controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manually controlled infusion of remifentanil (loading dose of 0.75 μg · kg and 0.075 μg · kg · min as maintenance)
Study: 16261287
Drug: MCC-135 (4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCC-135 (4.5 mg/kg/48 hours)
Study: 16261287
Drug: MCC-135 (9.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCC-135 (9.0 mg/kg/48 hours)
Study: 16261287
Drug: MCC-135 (4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCC-135 (4.5 mg/kg/48 hours) and MCC-135 (9.0 mg/kg/48 hours)
Study: 12239666
Drug: Collagenase injection
DrugBank: Collagenase clostridium histolyticum (DB00048)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Collagenase injection therapy (one dose)
Study: 12239666
Drug: Collagenase injection
DrugBank: Collagenase clostridium histolyticum (DB00048)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Collagenase injection therapy (dose-response study)
Study: 10665619
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT), delivered in 19 individual sessions over 9 months
Study: 8842506
Drug: Propafenone 300
Normalized name: propafenone 300 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone 300 mg tid
Study: 8842506
Drug: Disopyramide 250
Normalized name: disopyramide 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disopyramide 250 mg tid
Study: 6508975
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal 25 g administered 5 min after drug ingestion on an empty stomach
Study: 6508975
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal 25 g administered 60 min after drug ingestion on an empty stomach
Study: 6508975
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal 25 g administered 5 min after drug ingestion after a standard meal
Study: 6508975
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal 25 g administered 60 min after drug ingestion after a standard meal
Study: 30753449
Drug: CPR-retraining based
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPR-retraining based on hands-on rolling refreshers during the 2-month program (G-CPR, n = 53)
Study: 30753449
Drug: Standard one-time
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard one-time training (G-Stan, n = 61)
Study: 30753449
Drug: CPR-retraining (G-CPR)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPR-retraining (G-CPR)
Study: 25352865
Drug: 10% IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% IV dextrose infusion by burettes
Study: 16024305
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg once daily for 4-8 weeks
Study: 16024305
Drug: Maintenance with
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance with rabeprazole 10 mg or 2x10 mg once daily for a maximum of 48 weeks
Study: 9384841
Drug: Gradual discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gradual discontinuation of lithium
Study: 9384841
Drug: Sharp reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sharp reduction in lithium dose
Study: 9384841
Drug: Other disorders
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other disorders and treatments (neuroleptics in schizophrenia, antidepressants in recurrent depression)
Study: 3711599
Drug: High fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High fat breakfast followed by iv injection of 1000 u heparin (high NEFA protocol)
Study: 28635634
Drug: 4 +
Normalized name: MK-4 + MK-7
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 + 4 g/day oral EAAs
Study: 26233286
Drug: Decorated objects
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decorated objects (e.g., polka dots, feathers)
Study: 21210776
Drug: Berlin-Frankfürt-Münster-derived acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Berlin-Frankfürt-Münster-derived acute lymphoblastic leukaemia (ALL) therapy
Study: 17243596
Drug: G‐Bond (GBO,
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐Bond (GBO, GC)
Study: 15504183
Drug: Rocuronium 0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.03 mg kg(‐1)
Study: 11549539
Drug: Antioxidant supplementation
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplementation (250 mg of vitamin C, 50 IU of alpha-tocopherol, and 12 oz of vegetable cocktail daily for 2 weeks)
Study: 9029389
Drug: Cefazolin administered
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefazolin administered preoperatively (1 g)
Study: 9029389
Drug: Cefazolin administered
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefazolin administered after cord clamping (1 g)
Study: 8299661
Drug: Amlodipine 10
Normalized name: amlodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 10 mg once a day
Study: 30548375
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for psychosis (CBTp) or Metacognition‐Oriented Social Skills training
Study: 30554366
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment based on P. purpureum (PT) grass
Study: 16496307
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (3 g, intravenously, n = 15)
Study: 12492803
Drug: i.v. remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. remifentanil (1.5 micro g kg‐1, followed by 0.2 micro g kg‐1 min‐1)
Study: 12492803
Drug: i.v. sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. sufentanil (0.2 micro g kg‐1 followed by 0.2 micro g kg‐1 h‐1)
Study: 11736778
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion of ropivacaine 0.1% and sufentanil 1 microg x ml(‐1) at a rate of 5‐9 ml x h(‐1)
Study: 11736778
Drug: Intravenous patient‐controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous patient‐controlled analgesia using piritramide
Study: 11736778
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion of ropivacaine 0.1% and sufentanil 1 microg x ml(‐1)
Study: 2879458
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg of ipratropium bromide
Study: 2879458
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg of fenoterol hydrobromide
Study: 2879458
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg of ipratropium plus 1.25 mg of fenoterol
Study: 31757776
Drug: Online self-esteem
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Online self-esteem intervention (7 weekly sessions in Second Life)
Study: 28619115
Drug: Intervention Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention Group (IG) - 120 min/week walking (396 METs/min/week) and monthly sociocultural gatherings
Study: 20980335
Drug: Chemotherapy (temozolomide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (temozolomide or procarbazine/lomustine/vincristine)
Study: 16582025
Drug: KRG-rootlets (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: KRG-rootlets (6 g)
Study: 16582025
Drug: KRG-rootlets (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: KRG-rootlets (mean of 3 doses)
Study: 31350122
Drug: Lisdexamfetamine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisdexamfetamine (6 weeks treatment)
Study: 31350122
Drug: Placebo (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (6 weeks treatment)
Study: 23254732
Drug: Dexamethasone cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone cyclophosphamide pulse (DCP) therapy
Study: 19064982
Drug: Sunitinib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib (50 mg/d for 4 weeks, 2 weeks off)
Study: 2085986
Drug: Fosfomycin trometamol
Normalized name: trometamol
DrugBank: Tromethamine (DB03754)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fosfomycin trometamol (3 g)
Study: 7240438
Drug: Aspirin (3.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (3.25 Gm/day)
Study: 27053264
Drug: Guidelines and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guidelines and prompts (G&P)